


A'
B'
cont



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy[, hydroxy and halogen] when p is 2 and X is -O-;

[(R₁) is R₂₀, R₂₁, or R₂₂, wherein:

R₂₀ is -(CH₂)_n-, where n is 2, 3, 4 or 5;

[R₂₁ is

-CH₂-CH=CH-CH₂-,

-CH₂-C≡C-CH₂-,

-CH₂-CH=CH-CH₂-CH₂-,

-CH₂-CH₂-CH=CH-CH₂-,


-CH₂-C≡C-CH₂-CH₂-, or

-CH₂-CH₂-C≡C-CH₂-,

the -CH=CH- bond being cis or trans;

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted

by at least one C₁-C₆ linear alkyl group, phenyl group or




where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂ or halogen;]

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,] -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or -CH(OR₇)-alkyl[,]; [-C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;]


alkyl is lower alkyl;

aryl is phenyl or



where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine,
iodine, lower monoalkylamino, [lower dialkylamino,] nitro, cyano,
trifluoromethyl, trifluoromethoxy;

heteroaryl is



Q₃ is -O-, -S-, -NH-, or -CH=N-;

[W is CH₂ or CHR₈ or N-R₉;

R₇ is hydrogen, lower alkyl, or acyl;

[R₈ is lower alkyl;

R₉ is hydroxy, lower alkoxy, or -NHR₁₀; and

R₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above;] and

m is 1, 2, or 3;

[all geometric, optical and stereoisomers thereof,] or a pharmaceutically acceptable acid

addition salt thereof.

005116220

A2
psh
B3

00976260

52. (Amended) A compound as claimed in claim [1] 132, which is N,N-dimethyl-4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxybenzamide, or a pharmaceutically acceptable acid addition salt thereof.

53. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone oxime, or a pharmaceutically acceptable acid addition salt thereof.

54. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]methoxyphenyl]ethanone oxime O-methyl ether, or a pharmaceutically acceptable acid addition salt thereof.

55. (Amended) A compound as claimed in claim [1] 132, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-propoxy]-3-methoxyphenyl]ethanone hydrazone, or a pharmaceutically acceptable acid addition salt thereof.

56. (Amended) A compound as claimed in claim [1] 132, which is 6-fluoro-3-[1-[3-[2-methoxy-4-(1-methylethenyl)phenoxy]-propyl]-4-piperidinyl]-1,2-benzisoxazole, or a pharmaceutically acceptable acid addition salt thereof.

57. (Amended) A compound as claimed in claim [1] 87, which is (Z)-1-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.


58. (Amended) A compound as claimed in claim [1] 87, which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-hydroxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

59. (Amended) A compound as claimed in claim [1] 87, which is (E)-1-[3-[4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-4-benzyloxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

65. (Amended) A compound as claimed in claim [1] 104, which is 1-(R)-(-)-[4-[3-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-1-propoxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

66. (Amended) A compound as claimed in claim [1] 104, which is 1-(S)(+)-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-methyl-1-propoxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

78. (Amended) A compound of the formula:



wherein p is 1 or 2;

Y is hydrogen, Cl, Br, or F, when p is 1;

Y is lower alkoxy[, hydroxy, or halogen] when p is 2;

n is 2, 3, or 4;

R is hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, alkanoyl, Cl, F, Br, I, amino,

C₁-C₃ mono or dialkyl amino, acylamino, -NO₂, -OCF₃, -CF₃, alkyl-C(=O)-, CF₃-C(=O)-, or -CH(OR₇)-alkyl;

alkyl is lower alkyl;

R₇ is hydrogen, lower alkyl, lower alkyl-C(=O)-, or CF₃-C(=O)-;


and m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid addition salt thereof.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

79. (Amended) A compound of the formula:



wherein p is 1 or 2;

Y is hydrogen, Cl, Br, or F, when p is 1;

Y is lower alkoxy[, hydroxy, or halogen] when p is 2;

n is 2, 3, or 4;

R is hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, acyl, alkanoyl, Cl, F, Br, I, amino, C₁-

C₃ mono or dialkyl amino, acylamino, -NO₂, -OCF₃, -CF₃, alkyl-C(=O)-,

CF₃-C(=O)-, or -CH(OR₇)-alkyl;

alkyl is lower alkyl;

R₇ is hydrogen, lower alkyl, lower alkyl-C(=O)-, or CF₃-C(=O)-;

and m is 1, 2, or 3;


all geometric, optical and stereoisomers thereof or a pharmaceutically acceptable acid

addition salt thereof.

80. (Amended) A compound as claimed in claim 1 [of the formula:

a4

B6
cont



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy and halogen when p is 2 and X is -O-;

(R₁) is R₂₀, R₂₁, or R₂₂, wherein:

R₂₀ is -(CH₂)_n-, where n is 2, 3, 4 or 5;

R₂₁ is

-CH₂-CH=CH-CH₂-,

-CH₂-C≡C-CH₂-,

-CH₂-CH=CH-CH₂-CH₂-,

-CH₂-CH₂-CH=CH-CH₂-,

-CH₂-C≡C-CH₂-CH₂-, or

-CH₂-CH₂-C≡C-CH₂-,


the -CH=CH- bond being cis or trans;

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

by at least one C₁-C₆ linear alkyl group, phenyl group or



where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂ or halogen; and R

and m are as defined hereinafter;

m is 1, 2, or 3; and

when m is 1, 2, or 3, R is hydrogen, lower alkyl, lower alkoxy, hydroxyl,

carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or

dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino,

trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl,


dialkylaminocarbonyl, formyl,

-C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl,

-CH(OR₇)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;

alkyl is lower alkyl;

aryl is phenyl or



where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine,


iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano,

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

trifluoromethyl, trifluoromethoxy;

heteroaryl is



Q₃ is -O-, -S-, -NH-, or -CH=N-;

W is CH₂ or CHR₈ or N-R₉;

R₇ is hydrogen, lower alkyl, or acyl;

R₈ is lower alkyl;

R₉ is hydroxy, lower alkoxy, or -NHR₁₀; and

R₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above; and]

with the proviso that when m is 3, R is not -C(=O)-aryl, or -C(=O)-heteroaryl[;],

[all geometric, optical and stereoisomers thereof,] or a pharmaceutically acceptable acid addition salt thereof.

81. (Amended) A compound as claimed in claim [1] 87, which is (E)-1-[4-[[4-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-butenyl]oxy]-3-methoxyphenyl]ethanone, or a pharmaceutically acceptable acid addition salt thereof.

82. (Amended) A pharmaceutical composition, which comprises a compound as claimed in claims [1-81] 1-75 and 77-81, and a pharmaceutically acceptable carrier therefor.

83. (Amended) An antipsychotic composition which comprises a compound as claimed in claims [1-81] 1-75 and 77-81, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

84. (Amended) A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claims [1-81] 1-75 and 77-81.

85. (Amended) An analgesic composition which comprises a compound as claimed in claims [1-81] 1-75 and 77-81, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

86. (Amended) A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claims [1-81] 1-75 and 77-81.


87. A compound of the formula

A⁴
B⁶
cont

00511-02121-00

A⁵
sub
C³

a⁵
C³
cont



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is -O-;

(R₁) is

-CH₂-CH=CH-CH₂-;

-CH₂-C≡C-CH₂-;

-CH₂-CH=CH-CH₂-CH₂-;

-CH₂-CH₂-CH=CH-CH₂-;

-CH₂-C≡C-CH₂-CH₂-; or

-CH₂-CH₂-C≡C-CH₂-;


the -CH=CH- bond being cis or trans;

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl

thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl,


-CH(OR₇)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;

aryl is phenyl or



trifluoromethoxy;

heteroaryl is



R₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl, or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above; and

m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid
addition salt thereof.

88. The compound of claim 87, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids.

89. The compound of claim 88, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid.

90. The compound of claim 87, wherein Y is in the 5 position.

91. The compound of claim 87, wherein Y is in the 6 position.

92. The compound of claim 87, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine.

Q⁵
C³
cont

00511-0000

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

93. The compound of claim 92, wherein Y is fluorine.

94. The compound of claim 93, wherein Y is in the 6 position.

95. The compound of claim 87, wherein p is 2, X is -O-, and Y is selected from the group consisting of lower alkoxy, hydroxy and halogen groups.

96. The compound of claim 95, wherein Y is a methoxy group.

97. The compound of claim 87, wherein R₁ is -CH₂-CH=CH-CH₂-.

98. The compound of claim 87, wherein R is selected from the group consisting of hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, -COCF₃, C₁-C₆ alkanoyl, Cl, F, Br, I, C₁-C₃ alkylamino, -NO₃, -CF₃, -OCF₃, and -C(=O)-lower alkyl.

99. A pharmaceutical composition, which comprises a compound as claimed in claim 87, and a pharmaceutically acceptable carrier therefor.

100. An antipsychotic composition which comprises a compound as claimed in claim 87, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

LAW OFFICES


FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

101. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 87.

102. An analgesic composition which comprises a compound as claimed in claim 87, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

103. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 87.

104. A compound of the formula



wherein

X is -O- or -S-;

p is 1 or 2;


Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy,

trifluoromethyl, nitro, or amino, when p is 1;

Q5
C4
cont

Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is -O-;

(R₁) is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted by at least one C₁-C₆ linear alkyl group, phenyl group or



where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂ or halogen;

R₂₀ is -(CH₂)_n-, where n is 2, 3, 4 or 5;

R₂₁ is

-CH₂-CH=CH-CH₂-;

-CH₂-C≡C-CH₂-;

-CH₂-CH=CH-CH₂-CH₂-;

-CH₂-CH₂-CH=CH-CH₂-;

-CH₂-C≡C-CH₂-CH₂-; or

-CH₂-CH₂-C≡C-CH₂-;

the -CH=CH- bond being cis or trans;

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine,

iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio,

trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl,

aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,

LAW OFFICES


FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

-C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl,

-CH(OR₇)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;

where alkyl is lower alkyl;

aryl is phenyl or




where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine,

iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl,

trifluoromethoxy;

heteroaryl is



where Q₃ is -O-, -S-, -NH-, or -CH=N-;

W is CH₂ or CHR₈ or N-R₉;

R₇ is hydrogen, lower alkyl, or acyl;

R₈ is lower alkyl;

R₉ is hydroxy, lower alkoxy, or -NHR₁₀; and

R₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl, or -C(=O)-heteroaryl,

Q5
C4
cont

where aryl and heteroaryl are as defined above; and

m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid
addition salt thereof.

105. The compound of claim 104, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids.

106. The compound of claim 105, wherein said pharmaceutically acceptable addition salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid.

107. The compound of claim 104, wherein Y is in the 5 position.

108. The compound of claim 104, wherein Y is in the 6 position.

109. The compound of claim 104, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine.

110. The compound of claim 109, wherein Y is fluorine.

111. The compound of claim 110, wherein Y is in the 6 position.

112. The compound of claim 104, wherein p is 2, X is -O-, and Y is selected from the group consisting of lower alkoxy, hydroxy and halogen groups.

113. The compound of claim 112, wherein Y is a methoxy group.

114. The compound of claim 104, wherein R is selected from the group consisting of hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, -COCF₃, C₁-C₆ alkanoyl, Cl, F, Br, I, C₁-C₃ alkylamino, -NO₂, -CF₃, -OCF₃, and -C(=O)-lower alkyl.

115. A pharmaceutical composition, which comprises a compound as claimed claim 104, and a pharmaceutically acceptable carrier therefor.

116. An antipsychotic composition which comprises a compound as claimed in claim 104, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

117. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 104.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Q5
118. An analgesic composition which comprises a compound as claimed in claim 104, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

119. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 104.

120. A compound as claimed in claim 87, with the proviso that when m is 3, R is not -C(=O)-aryl, or -C(=O)-heteroaryl, all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

121. A pharmaceutical composition, which comprises a compound as claimed in claim 120, and a pharmaceutically acceptable carrier therefor.

122. An antipsychotic composition which comprises a compound as claimed in claim 120, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

123. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 120.

124. An analgesic composition which comprises a compound as claimed in claim 120, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

125. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 120.

126. A compound as claimed in claim 104, with the proviso that when m is 3, R is not -C(=O)-aryl, or -C(=O)-heteroaryl, all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.

127. A pharmaceutical composition, which comprises a compound as claimed in claim 126, and a pharmaceutically acceptable carrier therefor.


128. An antipsychotic composition which comprises a compound as claimed in claim 126, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

129. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 126.

130. An analgesic composition which comprises a compound as claimed in claim 126,
in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable
carrier therefor.

131. A method of alleviating pain, which comprises administering to a mammal a pain-
relieving effective amount of a compound as claimed in claim 126.

132. A compound of the formula



wherein

X is -O- or -S-;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy,

trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy, hydroxy, or halogen when p is 2 and X is -O-;

n is 2, 3, 4 or 5;

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine,

bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio,

trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl,


aminocarbonyl, dialkylaminocarbonyl, formyl,

-C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or

-CH(OR₇)-alkyl, -C(=W)-alkyl, -C(=W)-aryl, or -C(=W)-heteroaryl;

alkyl is lower alkyl;


aryl is phenyl or



where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine,

iodine, lower monoalkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy;

heteroaryl is



A⁵
B9
Conf

R₇ is hydrogen, lower alkyl, or acyl;

R₉ is hydroxy, lower alkoxy, or -NHR₁₀; and

R₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above; and

m is 1, 2, or 3;

with the proviso that at least one R is selected from the group consisting of

dialkylaminocarbonyl, formyl, -C(=W)-alkyl, C(=W)-aryl, and

-C(=W)-heteroaryl;

~~all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable acid~~

addition salt thereof.

133. The compound of claim 132, wherein the pharmaceutically acceptable addition salt is selected from the group consisting of salts of mineral acids, salts of monobasic carboxylic acids, salts of dibasic carboxylic acids, and salts of tribasic carboxylic acids.

134. The compound of claim 133, wherein said pharmaceutically acceptable addition

salts are selected from the group consisting of salts of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, propionic acid, maleic acid, fumaric acid, carboxysuccinic acid, and citric acid.

a⁵
135. The compound of claim 132, wherein Y is in the 5 position.

136. The compound of claim 132, wherein Y is in the 6 position.

137. The compound of claim 132, wherein Y is selected from the group consisting of hydrogen, chlorine, bromine and fluorine.

138. The compound of claim 137, wherein Y is fluorine.

139. The compound of claim 138, wherein Y is in the 6 position.

140. The compound of claim 132, wherein p is 2, X is -O-, and Y is selected from the group consisting of lower alkoxy, hydroxy and halogen groups.

141. The compound of claim 140, wherein Y is a methoxy group.

142. The compound of claim 132, wherein one R group is selected from the group consisting of hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, ~~COCF₃~~, C₁-C₆ alkanoyl, Cl, F, Br.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

B¹⁰
cont

I, C₁-C₃ alkylamino, -NO₃, -CF₃, -OCF₃, and -C(=O)-lower alkyl.

143. A pharmaceutical composition, which comprises a compound as claimed in claim 132, and a pharmaceutically acceptable carrier therefor.

144. An antipsychotic composition which comprises a compound as claimed in claim 132, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

145. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating effective amount of a compound as claimed in claim 132.

146. An analgesic composition which comprises a compound as claimed in claim 132, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.

147. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of a compound as claimed in claim 132.